Understanding The Potential Therapeutic Uses of WNK4 (G65266)
Understanding The Potential Therapeutic Uses of WNK4
Protein kinase lysine-deficient 4 (WNK4) is a gene that encodes a protein known as p181G, which is a key regulator of cell proliferation and survival. WNK4 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is involved in the regulation of cell growth, differentiation, and survival, and is considered a potential drug target or biomarker for various diseases.
The WNK4 gene was first identified in 2003 using DNA array analysis. The gene is located on chromosome 18 and encodes a protein of 21 kDa. WNK4 is predominantly expressed in the brain, heart, and kidneys, and is also found in various other tissues, including the liver, pancreas, and cervical uterus. The protein produced by the WNK4 gene is involved in the regulation of cell growth, differentiation, and survival, and is thought to play a key role in the development and progression of various diseases.
One of the key functions of WNK4 is its role in the regulation of cell growth and differentiation. WNK4 is involved in the regulation of cell proliferation by promoting the growth of cells and by inhibiting the growth of cells that are no longer needed. This is accomplished through the regulation of various cellular processes, including cell cycle progression, apoptosis, and angiogenesis.
In addition to its role in cell growth and differentiation, WNK4 is also involved in the regulation of cell survival. The protein produced by the WNK4 gene has been shown to play a role in the regulation of cell survival by promoting the survival of cells and by inhibiting the survival of cells that are no longer needed. This is accomplished through the regulation of various cellular processes, including the regulation of cell apoptosis, inflammation, and cellular signaling.
The potential drug target or biomarker properties of WNK4 are due to its involvement in the regulation of cell growth, differentiation, and survival. It is thought to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, targeting WNK4 with small molecules or other therapeutic agents may be a promising strategy for the treatment of these diseases.
In conclusion, WNK4 is a protein that is involved in the regulation of cell growth, differentiation, and survival. It is expressed in various tissues throughout the body and is considered a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of WNK4 in the development and progression of these diseases, as well as the potential therapeutic uses of WNK4.
Protein Name: WNK Lysine Deficient Protein Kinase 4
Functions: Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SCNN1A, SCNN1B, SCNN1D, SGK1, TRPV5 and TRPV6. Regulates the activity of the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation which appears to prevent membrane trafficking of SLC12A3. Also inhibits the renal K(+) channel, KCNJ1, via a kinase-independent mechanism by which it induces clearance of the protein from the cell surface by clathrin-dependent endocytosis. WNK4 appears to act as a molecular switch that can vary the balance between NaCl reabsorption and K(+) secretion to maintain integrated homeostasis. Phosphorylates NEDD4L. Acts as a scaffold to inhibit SLC4A4 as well as CFTR activities and surface expression, recruits STK39 which mediates the inhibition (By similarity)
The "WNK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNK4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1 | XRCC1 | XRCC2 | XRCC3 | XRCC4 | XRCC5 | XRCC6 | XRCC6P5 | XRN1
